Skip to content

Clinical Application Research of AI-Based Large Models for Early Screening, Diagnosis, Treatment, and Prognosis Assessment of Esophageal Cancer

Large-scale Models of Esophageal Cancer and Related Research

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600124579
Enrollment
Unknown
Registered
2026-05-14
Start date
2026-05-15
Completion date
Unknown
Last updated
2026-06-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophageal Cancer

Interventions

Oesophageal Lesion Group:none
Diagnostic and Therapeutic Model Group:none
Prognosis Prediction Group:none

Sponsors

The First Affiliated Hospital of Henan University of Science & Technology
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18 years or older. 2. Individuals with normal findings or inflammatory changes: endoscopic or pathological reports indicating "no significant abnormalities detected" or changes consistent with inflammation. 3. Individuals with benign lesions: pathological reports specifying "absence of tumor cells" or a diagnosis consistent with benign lesions. 4. Individuals with precancerous lesions: pathological reports with a definitive diagnosis of Low-grade Intraepithelial Neoplasia (LGIN) or High-grade Intraepithelial Neoplasia (HGIN). 5. Individuals with malignant tumors: pathological reports confirming a diagnosis of esophageal squamous cell carcinoma or esophageal adenocarcinoma.

Exclusion criteria

Exclusion criteria: 1. Diagnostically uncertain: Lack of definitive pathological evidence, or with doubtful clinical diagnosis. 2. Poor data quality: Low-quality key imaging data (endoscopy, CT) that is unsuitable for analysis (e.g., severe artifacts, missing images). 3. Severe missingness of key clinical or follow-up data (missing rate > 20%). 4. Confounding by other malignancies: Presence of other active malignant tumors other than esophageal cancer within 5 years prior to enrollment. 5. Loss to follow-up: Failure to obtain key survival or recurrence follow-up information in the retrospective cohort.

Design outcomes

Primary

MeasureTime frame
Area under the ROC curve;accuracy;C-index;

Countries

China

Contacts

Public ContactShegan Gao

The First Affiliated Hospital of Henan University of Science & Technology

fzswsys@163.com+86 379 6483 0609

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jun 11, 2026